Opinion
Video
Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity rates by approximately 10% at both the 10–5 and 10–6 levels, particularly benefiting high-risk patients.
The IsKia clinical trial demonstrated approximately 10% improvement in minimal residual disease (MRD) negativity rates when added to carfilzomib, lenalidomide, and dexamethasone, with consistent benefits observed at both the 10–5 and 10–6 levels. The trial included high-risk patients and those with double-hit genetics, showing ability to narrow the response gap between standard-risk and high-risk populations. Treatment abandonment rates remained similar between groups, indicating acceptable tolerability profiles for the quadruplet regimen.
International Myeloma Society risk stratification is evolving to better identify truly high-risk patients who require different treatment approaches. The refined definition focuses on patients with translocation plus additional abnormalities in 1q or 1p, and those with deletion 17p, representing approximately 15% to 20% of patients rather than the broader 40% previously classified as high risk. This more precise risk stratification aims to identify patients where current standard treatments are inadequate.
The ADMIRAL trial analysis of 1q21 patients demonstrated that approximately 40% of multiple myeloma patients have this abnormality, with clear benefit from isatuximab addition throughout their treatment journey. Patients with 1q abnormalities showed longer progression-free survival, better overall response rates, and increased MRD negativity when receiving continuous anti-CD38 therapy. These findings support the general principle that 4-drug combinations provide superior outcomes compared to 3-drug regimens across most patient populations.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.